Alvotech Partners with Sandoz to Expand Biosimilar Access Across Canada, Australia, and New Zealand
核心洞察
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates across Canada, Australia, and New Zealand.
The partnership includes one ophthalmology biosimilar for Canada and three biosimilars across immunology and gastroenterology for Australia and New Zealand.
Sandoz will handle regulatory submissions and commercialization while Alvotech retains responsibility for development, clinical activities, and manufacturing.
Alvotech, a global biotechnology company specializing in biosimilar medicines, has announced strategic supply and commercialization agreements with Sandoz to expand access to multiple biosimilar candidates across Canada, Australia, and New Zealand. The partnerships represent a significant step in Alvotech's strategy to secure commercial pathways for its biosimilars portfolio ahead of regulatory approval.
Strategic Partnership Details
Under the agreements, Sandoz will lead regulatory filings and commercial activities in the designated territories while working in close coordination with Alvotech. The collaboration encompasses different therapeutic areas across the regions, with Canada receiving coverage for one biosimilar candidate in ophthalmology and Australia and New Zealand gaining access to three biosimilar candidates across immunology and gastroenterology.
The Canadian agreement specifically covers one biosimilar candidate in ophthalmology supplied as a prefilled syringe for intravitreal injection. Meanwhile, the Australia and New Zealand agreement encompasses three biosimilar candidates available in multiple formulations across immunology and gastroenterology therapeutic areas.
Division of Responsibilities
The partnership establishes a clear division of responsibilities between the two companies. Sandoz will be responsible for regulatory submissions, commercialization, and distribution in the respective jurisdictions, leveraging its strong presence in Canada, Australia, and New Zealand. Alvotech will retain responsibility for development, global clinical activities, and manufacturing, supplying finished products to Sandoz under exclusive supply arrangements.
"These agreements with Sandoz further advance Alvotech's strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval," said Róbert Wessman, Chairman of Alvotech. "These partnerships reflect the strength of our integrated development and manufacturing platform and our ability to work with experienced regional partners to expand patient access while maintaining capital discipline."
Alvotech's Biosimilar Portfolio
Alvotech has established itself as a significant player in the biosimilar space, with five biosimilars already approved and marketed in multiple global markets. These include biosimilars to major biologic drugs such as Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab).
The company's current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders (搜索), eye disorders (搜索), osteoporosis (搜索), respiratory disease (搜索), and cancer (搜索). This robust pipeline positions Alvotech to address multiple therapeutic areas where biosimilars can provide cost-effective alternatives to expensive biologic medicines.
Market Access Strategy
The collaboration with Sandoz is part of Alvotech's broader strategy to form a network of strategic commercial partnerships that provide global reach and leverage local expertise. The company has established partnerships in markets including the United States, Europe, Japan, China, other Asian countries, and large parts of South America, Africa, and the Middle East.
With Sandoz's commitment to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, the partnership is intended to support broad patient access following regulatory approvals and market launches across the region. This approach aligns with the growing global emphasis on making biologic therapies more accessible through biosimilar alternatives.